Other previous studies failed to demonstrate a relevant clinical benefit in patients with metastatic TNBC treated with ICB, as the KEYNOTE-012 [49] and the KEYNOTE-119 [50], which assessed the role of pembrolizumab in metastatic TNBC, underscoring the heterogeneity of BRCA1/2-deficient breast cancers with respect to immunogenicity. Here, BRCA1 is linked to breast cancer.